WO2005072397A3 - Systeme de liberations multiples de medicament specifique a la voie gastro-intestinale - Google Patents

Systeme de liberations multiples de medicament specifique a la voie gastro-intestinale Download PDF

Info

Publication number
WO2005072397A3
WO2005072397A3 PCT/US2005/002679 US2005002679W WO2005072397A3 WO 2005072397 A3 WO2005072397 A3 WO 2005072397A3 US 2005002679 W US2005002679 W US 2005002679W WO 2005072397 A3 WO2005072397 A3 WO 2005072397A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
gastrointestinal
release system
drug release
multiple drug
Prior art date
Application number
PCT/US2005/002679
Other languages
English (en)
Other versions
WO2005072397A2 (fr
Inventor
Keiko Tsutsumi
James Shunnan Chu
Original Assignee
Yamanouchi Pharma Tech Inc
Keiko Tsutsumi
James Shunnan Chu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Tech Inc, Keiko Tsutsumi, James Shunnan Chu filed Critical Yamanouchi Pharma Tech Inc
Priority to JP2006551492A priority Critical patent/JP2007519741A/ja
Publication of WO2005072397A2 publication Critical patent/WO2005072397A2/fr
Publication of WO2005072397A3 publication Critical patent/WO2005072397A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des méthodes pour plusieurs libérations d'un médicament dans la voie gastro-intestinale d'un patient, faisant appel à l'utilisation d'un système à libérations orales multiples de médicaments. Ce système permet une libération spécifique à un site du médicament, à la fois dans l'intestin grêle et dans le colon, sous la forme de doses multiples contrôlées, pour une efficacité de longue durée, ce qui permet de réduire la fréquence de dosage de médicaments.
PCT/US2005/002679 2004-01-29 2005-01-28 Systeme de liberations multiples de medicament specifique a la voie gastro-intestinale WO2005072397A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006551492A JP2007519741A (ja) 2004-01-29 2005-01-28 胃腸特異的複数薬物放出システム

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54068204P 2004-01-29 2004-01-29
US60/540,682 2004-01-29
US11/046,517 2005-01-27
US11/046,517 US7670624B2 (en) 2004-01-29 2005-01-27 Gastrointestinal-specific multiple drug release system

Publications (2)

Publication Number Publication Date
WO2005072397A2 WO2005072397A2 (fr) 2005-08-11
WO2005072397A3 true WO2005072397A3 (fr) 2006-05-11

Family

ID=34829805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/002679 WO2005072397A2 (fr) 2004-01-29 2005-01-28 Systeme de liberations multiples de medicament specifique a la voie gastro-intestinale

Country Status (3)

Country Link
US (2) US7670624B2 (fr)
JP (1) JP2007519741A (fr)
WO (1) WO2005072397A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
DE10333443A1 (de) * 2003-07-23 2005-02-10 Goldschmidt Ag Emulgator für dünnflüssige W/O-Emulsionen auf Basis von teilvernetzten Polyglycerinestern der Polyhydroxystearinsäure
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
JP2008525313A (ja) 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
CA2613178A1 (fr) * 2005-07-15 2007-01-25 Kissei Pharmaceutical Co., Ltd. Preparation a liberation prolongee
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
AU2012202620B2 (en) * 2007-02-20 2014-03-20 Allergan Therapeutics LLC Stable digestive enzyme compositions
PT2079445E (pt) * 2007-02-20 2016-02-29 Allergan Pharmaceuticals Internat Ltd Composições de enzimas digestivas estáveis
US20120027855A1 (en) * 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
WO2009048073A1 (fr) * 2007-10-09 2009-04-16 Takeda Pharmaceutical Company Limited Procédé d'enrobage de granules
RS51313B (sr) * 2007-11-09 2010-12-31 Acino Pharma Ag.51311 Retard tablete sa hidromorfonom
WO2009109856A2 (fr) 2008-03-07 2009-09-11 Axcan Pharma Inc. Procédé pour détecter un parvovirus infectieux dans des préparations pharmaceutiques
WO2009119290A1 (fr) * 2008-03-28 2009-10-01 リンテック株式会社 Préparation orale
RU2410100C2 (ru) * 2009-03-30 2011-01-27 Александр Владимирович Диковский Фармацевтическая композиция ингибитора протонной помпы и пребиотика для лечения язвенных поражений желудка и 12-перстной кишки
SI2570120T1 (en) 2010-06-08 2018-04-30 Kobe Gakuin Educational Foundation Coated particle and method for the production of coated particles
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
CN103221036A (zh) 2010-10-01 2013-07-24 阿普塔利斯制药有限公司 肠溶包衣的低强度胰脂肪酶制剂
AU2011326872C1 (en) * 2010-11-08 2015-02-19 Albireo Ab A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
CN103442727B (zh) 2011-02-11 2016-08-10 Zx制药有限责任公司 多微粒l-薄荷醇制剂及相关方法
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
DK2741766T3 (en) 2011-08-08 2016-01-11 Aptalis Pharma Ltd Process for dissolving solid compositions containing digestive enzymes
JP2014529630A (ja) * 2011-09-07 2014-11-13 ザウラー−ブロシュ、ローラント 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
JP5102401B1 (ja) * 2012-03-30 2012-12-19 森下仁丹株式会社 大腸特異崩壊性カプセル
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EP2906202A4 (fr) * 2012-10-15 2016-04-27 Isa Odidi Formulations de médicament pour administration par voie orale
WO2014096983A1 (fr) 2012-12-21 2014-06-26 Wockhardt Limited Compositions pharmaceutiques stables de saxagliptin ou des sels de celui-ci
US20150250734A1 (en) 2012-12-21 2015-09-10 Wockhardt Limited Stable pharmaceutical compositions of saxagliptin or salts thereof
WO2014160633A1 (fr) 2013-03-24 2014-10-02 Xenoport, Inc. Compositions pharmaceutiques de fumarate de diméthyle
RS58325B1 (sr) 2013-04-23 2019-03-29 Zx Pharma Llc Enterosolventno obloženi višečestični preparat sa proteinskom sub-oblogom
CA2920844A1 (fr) 2013-08-09 2015-02-12 Allergan Pharmaceuticals International Limited Composition d'enzymes digestives appropriee pour une administration enterale
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
KR101410859B1 (ko) * 2013-10-14 2014-07-01 (주) 포스텍글로벌 수중 부상 및 부유가 방지된 피복 입상 비료 및 이의 제조방법
CN104739798A (zh) * 2013-12-26 2015-07-01 康普药业股份有限公司 一种白消安缓释片及其制备方法
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2015157428A1 (fr) * 2014-04-08 2015-10-15 Mayo Foundation For Medical Education And Research Capsule ingérable
AU2015275860A1 (en) 2014-06-19 2016-11-03 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
CA2910865C (fr) 2014-07-15 2016-11-29 Isa Odidi Compositions et methodes destines a reduire les surdoses
US10716761B2 (en) 2017-07-24 2020-07-21 Alcresta Therapeutics, Inc. Ingestible medical delivery devices
CN115715184A (zh) * 2021-06-23 2023-02-24 赛乐医药科技有限公司 替格瑞洛口服剂型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794367B1 (en) * 1998-05-19 2004-09-21 Hisamitsu Pharmaceutical, Inc. Solid preparations for oral administration of drugs relating to genes
US20050020282A1 (en) * 2001-05-21 2005-01-27 Ashutosh Pande Virtual satellite position system server

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
JPS6261916A (ja) * 1985-09-12 1987-03-18 Fujisawa Pharmaceut Co Ltd 持続性製剤
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
CA1338596C (fr) * 1988-09-27 1996-09-17 Hiroyoshi Koyama Granules possedant un noyau et leur production
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
HU210497B (en) 1990-05-04 1995-04-28 Perio Prod Ltd Process for production of modified pectin
JPH064531B2 (ja) 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
JPH0466538A (ja) 1990-07-04 1992-03-02 Suntory Ltd 抗潰瘍剤
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JP3069458B2 (ja) * 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
JPH05310558A (ja) 1992-05-07 1993-11-22 Lion Corp 固形製剤組成物
JP3059004B2 (ja) 1992-09-18 2000-07-04 ダイセル化学工業株式会社 アルカリ水溶液に対する溶解性の高い低置換度ヒドロキシプロピルセルロース及びその製造法
JPH06218028A (ja) 1992-10-02 1994-08-09 Eisai Co Ltd 湿製錠の成型方法とその装置及び湿製錠
US5654004A (en) * 1992-11-06 1997-08-05 Hisamitsu Pharmaceutical Co., Inc. Oral pharmaceutical preparation releasable in the lower digestive tract
WO1994013791A1 (fr) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Acide nucleique regulable a usage therapeutique et procedes d'utilisation associes
WO1994016057A1 (fr) * 1992-12-31 1994-07-21 Dana-Farber Cancer Institute, Inc. Sequence amplificatrice modulant l'expression dans les cellules epitheliales
WO1994016736A1 (fr) * 1993-01-22 1994-08-04 University Research Corporation Localisation d'agents therapeutiques
JPH06305962A (ja) 1993-04-21 1994-11-01 Taisho Pharmaceut Co Ltd アトピー性皮膚炎治療剤
JP3502951B2 (ja) 1993-07-06 2004-03-02 大正製薬株式会社 高脂血症治療剤
ES2179079T3 (es) * 1993-10-12 2003-01-16 Mitsubishi Pharma Corp Comprimidos que contienen granulos entericos.
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
CA2179382C (fr) 1994-01-31 2009-11-10 Takao Mizumoto Produits moules comprimes se dissolvant dans la bouche et procede de fabrication
AU689250B2 (en) 1994-04-22 1998-03-26 Astellas Pharma Inc. Colon-specific drug release system
JPH1135451A (ja) 1994-07-27 1999-02-09 Yamanouchi Pharmaceut Co Ltd 口腔内溶解型錠剤およびその製造方法
US5736388A (en) * 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
JPH08310969A (ja) 1995-05-22 1996-11-26 Lion Corp 固形薬品組成物及びその製造方法
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
JPH0948726A (ja) 1995-08-07 1997-02-18 Tanabe Seiyaku Co Ltd 口腔内速崩壊性製剤およびその製法
JPH0971523A (ja) 1995-09-07 1997-03-18 Riyuukakusan:Kk 口腔内で崩壊性の速い錠剤
ES2180972T3 (es) * 1996-05-09 2003-02-16 Sankyo Co Composicion contra el helicobacter pilori que contiene derivados de 1-metilcarbapenem como ingrediente activo.
RU2189227C2 (ru) 1996-07-12 2002-09-20 Дайити Фармасьютикал Ко., Лтд. Быстро распадающиеся прессованные в формах материалы и способ их получения
WO1998005310A1 (fr) * 1996-08-02 1998-02-12 Hisamitsu Pharmaceutical Co., Inc. Gelules destinees a des preparations orales et preparations de gelules destinees a une administration orale
US5714679A (en) * 1996-10-02 1998-02-03 Nichols; Steven J. Portable apparatus for testing an internal combustion engine
EP0839526A3 (fr) 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Préparation pharmaceutique solide à dissolution ou désintégration buccale rapide
US5840322A (en) * 1996-12-19 1998-11-24 Ramot-University Authority For Applied Research & Industrial Devel. Ltd. Anti-oral-microbial adhesion fraction derived from vaccinium
AU741242B2 (en) * 1997-05-20 2001-11-29 Ludwig Institute For Cancer Research Smad2 phosphorylation and interaction with Smad4
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
JP4939680B2 (ja) 1997-05-27 2012-05-30 武田薬品工業株式会社 固形製剤
JP3950175B2 (ja) * 1997-05-30 2007-07-25 オスモティカ・コーポレイション 多層浸透デバイス
JP3591801B2 (ja) 1997-06-19 2004-11-24 田辺製薬株式会社 口腔内速崩壊性製剤の製法
JP4196417B2 (ja) 1997-06-27 2008-12-17 大正製薬株式会社 口腔内速崩錠及びその製造方法
US6151525A (en) * 1997-11-07 2000-11-21 Medtronic, Inc. Method and system for myocardial identifier repair
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
AU4802099A (en) 1998-07-28 2000-02-21 Takeda Chemical Industries Ltd. Rapidly disintegrable solid preparation
JP2000178183A (ja) 1998-12-17 2000-06-27 Lion Corp 固形製剤及びその製造方法
DE19956486A1 (de) * 1999-11-24 2001-06-21 Lohmann Therapie Syst Lts Mehrschichtige Zubereitung zur gesteuerten, pulsartigen Abgabe von Wirkstoffen
US6569456B2 (en) * 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
WO2003028706A1 (fr) * 2001-09-28 2003-04-10 Sanwa Kagaku Kenkyusho Co.,Ltd Double comprime a desintegration rapide
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794367B1 (en) * 1998-05-19 2004-09-21 Hisamitsu Pharmaceutical, Inc. Solid preparations for oral administration of drugs relating to genes
US20050020282A1 (en) * 2001-05-21 2005-01-27 Ashutosh Pande Virtual satellite position system server

Also Published As

Publication number Publication date
US20050208133A1 (en) 2005-09-22
US20100183713A1 (en) 2010-07-22
WO2005072397A2 (fr) 2005-08-11
US7670624B2 (en) 2010-03-02
JP2007519741A (ja) 2007-07-19

Similar Documents

Publication Publication Date Title
WO2005072397A3 (fr) Systeme de liberations multiples de medicament specifique a la voie gastro-intestinale
WO2008085765A3 (fr) Formes dosifiées de petit volume de médicament contenant du sufentanil s'administrant par voie trans-muqueuse orale pour le traitement de la douleur
CA3094580C (fr) Formulations orales d'analogues de cytidine et leurs procedes d'utilisation
PT1827396T (pt) Medicamento oral de libertação modificada de pelo menos um princípio ativo sob forma multimicrocapsular
IL191804A0 (en) Solid dispersion containing an active ingredient and tablets for oral administration containing the same
EP1556010A4 (fr) Formulations pharmaceutiques ciblant des regions specifiques du tractus gastro-intestinal
EP2258350A3 (fr) Forme de dosage cachant le goût comprenant du roflumilas
SI1695710T1 (sl) Kristalna oblika beta-d ivabradin-hidroklorida, postopek za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo
ZA200704661B (en) Solid, orally appliance pharmaceutical administration forms containing rivaroxaban having modified release
WO2006124047A3 (fr) Formulations pharmaceutiques contenant des microparticules ou des nanoparticules d'un agent d'administration
EP2007398A4 (fr) Vitesses d'administration élevées pour préparations médicamenteuses lipidiques et méthodes de traitement associées
IL229304A (en) Compounds 1 ', 3' - Imaging Converts - 4 - Phenyl - 3, 4, 5, 6 - Tetrahydro - 2h, 1'h, [1, 4 '] Bipyridinyl - 2' - lozenges, pharmaceutical preparations containing them and their use
EP1757273A4 (fr) Preparation pour administration orale
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
EP1919288A4 (fr) Medicaments contenant famotidine et ibuprofene, et administration desdits medicaments
IL178425A0 (en) Carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
MX354416B (es) Formulaciones a base de nalbufina y sus usos.
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
WO2008003050A3 (fr) Formulations de nitrate de gallium
EP1942877A4 (fr) Formulations de doses orales d'ibuprofene organoleptiquement acceptables, procedes de preparation et d'utilisation de celles-ci
HK1100352A1 (en) Solid medicament of oral administration and preparation thereof
HK1120417A1 (en) Stable nanoparticle formulations
IL179014A0 (en) Film-shaped medicament for oral administration, containing estriol
IL179697A0 (en) Variants of unc5h2, their preparation and pharmaceutical compositions containing them
IL191783A0 (en) Pyrimidyl and fused pyrimidyl hydrazones, their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2006551492

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase